跳至主要内容
临床试验/ISRCTN80812769
ISRCTN80812769已完成3 期

A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer

Velindre NHS Trust (UK)0 个研究点目标入组 2,202 人开始时间: 2005年7月8日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
2,202

研究概览

简要总结

2009 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/19807917 protocol 2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26700124 results 2016 Results article in https://www.ncbi.nlm.nih.gov/pubmed/27439472 results

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Patients with histopathologically or cytologically confirmed primary lung cancer of any stage or histology.

排除标准

  • 1. Patients with other intrathoracic tumours (e.g. carcinoid, mesothelioma, lymphoma, lung metastases from another primary site)
  • 2. Any previous illness or treatment likely to interfere with protocol treatment or comparisons
  • 3. Known cerebral metastases
  • 4. Haemoptysis of CTC Grade two (symptomatic haemoptysis requiring medical intervention) or above
  • 5. Known bleeding diathesis
  • 6. Known pregnancy or lactation
  • 7. Known allergy to heparin
  • 8. Platelet count lower than 100 x 10^9/l
  • 9. Renal impairment with serum creatinine greater than 150 µmol/l
  • 10. Patients who have received therapeutic anticoagulation in the last 12 months
  • 11. Patients taking Ketorolac

研究者

发起方
Velindre NHS Trust (UK)

相似试验